

**PRESS RELEASE**

June 6, 2023

Rebirthel Co., Ltd.  
Room 311, Creation Core Kyoto Mikuruma  
448-5 Kajii-cho, Kamigyo-ku, Kyoto, Japan 602-0841  
Phone: (81) 75-212-3770  
URL: <https://rebirthel.com/en/>

Rebirthel Co., Ltd.

**Rebirthel signs Strategic Alliance Agreement with H.U. Group Research Institute G.K.  
to develop next-generation immune cell therapy based on Rebirthel's patented  
technology to produce universal allogeneic T cells**

Kyoto - Rebirthel Co., Ltd. (Rebirthel) announced that it has entered into a strategic alliance agreement with H.U. Group Research Institute G.K. (H.U. Group) on April 1, 2023 to develop next-generation immune cell therapy based on Rebirthel's technology to produce universal allogeneic T cell\*1.

In recent years, “autologous immune cell therapy\*2” using patient’s own cells has been recognized as an effective treatment for certain types of cancers. However, there are some issues: it can only be used for the donor patient; it is a burden on the patient's body; it takes long to start the treatment; the cost is high; and heterogeneous quality. In addition, infectious diseases require rapid treatment but autologous cell therapy cannot immediately provide killer T cells\*3. As a result, there is currently no existing cell therapy for infectious diseases. To address these limitations, Rebirthel provides a completely novel “allogeneic immune cell therapy”. Specifically, this method uses pluripotent stem cells as a source material and regenerates them into immune cells that specifically recognize and kill cancers or viruses.

H.U. Group Research Institute G.K. was established in July 2017 to consolidate basic research functions under the H.U. Group for development of products and services that will benefit society in the medium and long term. H.U. Group focuses on i) innovative analysis platforms, ii) basic medical innovation technologies, and iii) medical information

utilization. They are actively promoting open innovation with external research institutions, joint ventures, and different industries.

With a philosophy of rapid testing and development, H.U. Group aims to lead the industry by establishing new businesses. These include cell therapy and regenerative medicine, expanding advanced therapeutic modalities for future treatment. They aim to create new value in the healthcare field beyond testing and analysis.

H.U. Group and Rebirthel have begun joint research to add new-generation functions to the universal allogeneic immune cell therapy technology that Rebirthel is developing for clinical application. Through this strategic alliance, H.U. Group and Rebirthel will anticipate the needs of the next-generation of allogeneic immune cell therapies and accelerate research and development to provide them to society.

We believe allogeneic immune cell therapy will become a mainstream treatment in cancer immunotherapy. The history of biotechnology shows that even the most advanced technology can become outdated if it doesn't meet society's requirements for improved function. With this partnership, we aim to develop a more highly advanced functional allogeneic immune cell therapy and deliver it to patients who urgently require it.

< Epexegetis >

\*1 Allogeneic T cell: Using pluripotent stem cells (cells derived from others, not from the patient himself/herself) such as iPS and ES cells as material, T cells are regenerated and used for treatment.

\*2 Autologous immune cell therapy: This therapy collects the patient's own cells and gives them back after transducing and expanding.

\*3 Killer T cell: A type of cell that specifically recognizes variant cells (e.g., cancer cells) and viruses in the human body and controls immunity to attack and kill them.